Over the past three years, Synmosa has gained significant traction in the market with its respiratory product, Acetylcysteine. Not only has the company secured drug approval in China, but it has also strategically positioned itself in the Chinese market through competitive bidding processes, leading to sustained growth in both revenue and profit, hitting record highs. This success can be attributed to over a decade of continuous mergers and, more recently, aggressive strategic alliances to introduce branded drugs to the market. Over the past three years, Synmosa’s revenue has surged from NT$3.2 billion to NT$4.4 billion, and in 2023, it surpassed the NT$5 billion mark, reaching NT$5.14 billion.
Chairman Chih-Hui Lin has set an ambitious goal for the company: reaching NT$10 billion in revenue by 2026, positioning Synmosa as a major regional pharmaceutical company. From Acetylcysteine to nasal sprays, Synmosa’s products have benefitted from strong market demand, driving sales and allowing the company to effectively fill market gaps, thereby continuously increasing its market share.
Additionally, strategic alliances with Japanese pharmaceutical companies to introduce branded drugs are expected to receive approvals throughout this year, further boosting revenue and profit growth.
With these strategic moves, Synmosa is well on its way to achieving its billion-dollar revenue target, solidifying its position as a key player in the pharmaceutical industry.
Resource (Mandarin):
